Retatrutide
Retatrutide is the most powerful weight loss compound currently in clinical development. It works by simultaneously activating three different hormone receptor systems: GLP-1 (glucagon- like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon. This triple mechanism of action is why it produces significantly better weight loss results than semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound) in […]
Tirzepatide
Tirzepatide is a dual receptor agonist that changed what was thought possible with weight loss pharmacotherapy. It activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, and this combination produces significantly better results than GLP-1 drugs alone. In the SURMOUNT-1 trial, tirzepatide produced an average weight loss of 22.5% at the highest […]
Orforglipron (BioZapetite)
Orforglipron (LY3502970), marketed in the research peptide space under the name BioZapetite at a standard investigational dose of 6 mg, represents a paradigm shift in GLP-1 receptor agonist pharmacology. Unlike…
Semaglutide
Long-acting GLP-1 receptor agonist with extensive clinical trial data across metabolic and cardiovascular endpoints.